PRF Technologies (PRFX) Cash from Operations (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Cash from Operations of 3530000.0 for Q2 2024, up 276.24% year-on-year from 938241.77 in Q3 2023, and up 195.53% on a QoQ basis from 3695000.0 in Q1 2024.
PRF Technologies (PRFX) Cash from Operations (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Cash from Operations for 5 consecutive years, with 3530000.0 the latest figure, recorded in Q2 2024.
- Quarterly Cash from Operations rose 276.24% year-over-year to 3530000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 2889000.0 (up 62.55% YoY) and the FY2025 annual result came in at 3955000.0, up 68.66% from the prior year.
- Cash from Operations improved to 3530000.0 in Q2 2024 per PRFX's latest filing, from 3695000.0 in the prior quarter.
- Over the last five years, Cash from Operations for PRFX reached as high as 4775447000.0 in Q4 2021 and fell as low as 4778576000.0 in Q3 2021.
- A 5-year average of 1245166.67 and a median of 1571500.0 in 2022 frame the typical range for Cash from Operations.
- The largest YoY upside for Cash from Operations was 236157.69% in 2021 against a maximum downside of 2181898.17% in 2021.
- Year by year, Cash from Operations stood at 2023000.0 in 2020, then soared by 236157.69% to 4775447000.0 in 2021, then sank by 100.06% to 2868000.0 in 2022, then surged by 45.89% to 1552000.0 in 2023, then jumped by 327.45% to 3530000.0 in 2024.
- According to Business Quant data, Cash from Operations over the past three periods registered 3530000.0, 3695000.0, and 1552000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | -3.70 Mn |
| Mar 31, 2024 | -3.70 Mn |
| Dec 31, 2023 | -1.55 Mn |
| Dec 31, 2023 | -1.55 Mn |
| Sep 30, 2023 | -1.17 Mn |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -1.95 Mn |
| Mar 31, 2023 | -1.95 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Sep 30, 2022 | -892,000.00 |
| Sep 30, 2022 | -892,000.00 |
| Jun 30, 2022 | -1.59 Mn |
| Jun 30, 2022 | -1.59 Mn |
| Mar 31, 2022 | -1.11 Mn |
| Mar 31, 2022 | -1.11 Mn |